Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan vs Oxaliplatin/5-FU/Leucovorin in Advanced Colorectal Cancer
NCT00005036Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 1999
- Primary completion
- Dec 2006
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin in colorectal cancer (CRC), sponsored by National Cancer Institute. Started Nov 1999; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00005036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005036.